Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
about
Smallpox vaccines for biodefense: need and feasibilityA protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8DNA vaccines for biodefense.Human T-cell responses to vaccinia virus envelope proteins.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsPolyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection modelThe vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteinsA vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigensVaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge.Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challengeDisparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Antibody responses to vaccinia membrane proteins after smallpox vaccination.Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.Smallpox vaccines for biodefense.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.The strategic use of novel smallpox vaccines in the post-eradication world.Defending against smallpox: a focus on vaccines.Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.Myxoma Virus M083 is a virulence factor which mediates systemic dissemination.Immunogenicity and Protective Efficacy of a Polyvalent DNA Vaccine against Human Orthopoxvirus Infections Based on Smallpox Virus Genes
P2860
Q22305942-9D5F8E43-E2C6-45CC-9596-7D5BC14F966EQ30445071-60968546-96BD-44AD-9C51-AF7F7ABBC981Q33508318-60CA70D5-5FEC-4085-923F-B90ABCAAC04DQ33932404-4AE965E9-DD13-480B-AA5F-EDDBED35EA19Q34614260-DCE40C15-9ADC-41FD-ADDE-58AAB4F20D6EQ35101531-A502571F-9ECA-4187-B62F-4993D0A4897EQ35192889-EBEE6AB6-A732-4C9A-8366-58BFE4288024Q35339702-87C8F9EA-BE6F-4EB2-AFDF-FCD44833FBDAQ35760869-1DA60ADB-B6BD-4852-8203-4AA86D67A6A5Q35826728-083F4E61-6924-46BA-BEE1-9ACBA2297597Q35830974-2CBF739B-F1AA-4507-BE8E-A60B555DAB0AQ35948047-981BB09A-0E5B-4800-8ED8-411707A88E9CQ35963805-3508BF0B-F8FC-4066-BE27-1EFFB6370A41Q36391900-BF376A87-13C4-40B1-BEA4-29E348B53977Q36477717-8480C34D-19E3-4914-BB76-7A9533135C20Q36488876-34F38193-1B1F-40B0-8F3C-0260F9604332Q36498244-BE4D81DA-67AE-4304-8318-5FBB171F5E0CQ36845650-CF5F2FE0-5596-4FDF-96E5-A0F2717F8736Q36869365-FE219D62-BD70-4A9F-93E3-F4FC1DAF2A88Q37349246-C5A153C6-84B1-4827-AE76-D67EF410A1BBQ37375372-B5EB4BD7-F8C4-4265-99F7-C386798BAEB2Q37393765-0A19E700-C855-44F2-8ABE-EE93D2952DE2Q37461110-616FFA5A-B27A-448D-9952-C931571A306BQ37524022-90D67866-8BAA-46E5-B2D3-20ECF8E54A8BQ37909421-5F3F61DD-DFF8-4055-813A-955ADC98BFD3Q38799357-89A1CDFE-5550-4FDA-8F6F-0DEBDA1314B8Q40153814-A57080F2-FF00-4D0D-945E-96D95E0A65F6Q41039943-5D9F9E9C-08C8-48F4-BF34-AEA04D979380Q47155945-D6BF5262-F816-4E22-B231-06F9C83133C0Q47552286-5AF075D6-560B-4B1E-B1C9-D315205F7CDDQ58919934-229AFD1F-206B-462A-B327-D09EF7E657E3
P2860
Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Differential efficacy of vacci ...... intranasal poxvirus challenge.
@en
type
label
Differential efficacy of vacci ...... intranasal poxvirus challenge.
@en
prefLabel
Differential efficacy of vacci ...... intranasal poxvirus challenge.
@en
P2093
P1433
P1476
Differential efficacy of vacci ...... intranasal poxvirus challenge.
@en
P2093
P304
P356
10.1016/J.VACCINE.2004.02.034
P407
P577
2004-09-01T00:00:00Z